Meridian Clinical Research

Washington D.C., District of Columbia 20016

0 studies enrolling now · 3 studies all time

What they study most

Human Metapneumovirus, Human Metapneumovirus and Human Parainfluenza Infection, Respiratory Syncytial Virus, SARS-CoV-2

Studies at this site

• A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months — Running, not enrolling
• A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age — Completed
• Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure — Completed